BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16625509)

  • 1. [Anticholinesterases in the treatment of Alzheimer's disease].
    Gandía L; Alvarez RM; Hernández-Guijo JM; González-Rubio JM; de Pascual R; Rojo J; Tapia L
    Rev Neurol; 2006 Apr 16-30; 42(8):471-7. PubMed ID: 16625509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurotransmitters in Alzheimer's disease].
    Manzano-Palomo S; De la Morena-Vicente MA; Barquero MS
    Rev Neurol; 2006 Mar 16-31; 42(6):350-3. PubMed ID: 16575771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acetylcholinesterase inhibitors for treatment of Alzheimer's disease].
    Shinagawa S; Shigeta M
    Brain Nerve; 2014 May; 66(5):507-16. PubMed ID: 24807367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Alzheimer's disease].
    López OL; Becker JT
    Rev Neurol; 2002 Nov 1-15; 35(9):850-9. PubMed ID: 12436384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington.
    Davis KL
    Geriatrics; 1999 Feb; 54(2):42-7; quiz 48. PubMed ID: 10024872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M; Kálmán J
    Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinergic function and Alzheimer's disease.
    Giacobini E
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S1-5. PubMed ID: 12973744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
    León R; Garcia AG; Marco-Contelles J
    Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neurobiology and pharmacotherapy of Alzheimer's disease.
    Felician O; Sandson TA
    J Neuropsychiatry Clin Neurosci; 1999; 11(1):19-31. PubMed ID: 9990552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
    da Silva CH; Campo VL; Carvalho I; Taft CA
    J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease.
    Villarroya M; García AG; Marco JL
    Curr Pharm Des; 2004; 10(25):3177-84. PubMed ID: 15544507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cholinergic system in aging and neuronal degeneration.
    Schliebs R; Arendt T
    Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation.
    Brenner T; Nizri E; Irony-Tur-Sinai M; Hamra-Amitay Y; Wirguin I
    J Neuroimmunol; 2008 Sep; 201-202():121-7. PubMed ID: 18684515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New therapeutic options in Alzheimer's disease].
    García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
    Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG; Li B; Darvesh S; Lockridge O
    Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors.
    Tayeb HO; Yang HD; Price BH; Tarazi FI
    Pharmacol Ther; 2012 Apr; 134(1):8-25. PubMed ID: 22198801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.